| Literature DB >> 28234026 |
Alexandre A Lussier1,2, Joanne Weinberg2, Michael S Kobor1,3.
Abstract
Adverse in utero events can alter the development and function of numerous physiological systems, giving rise to lasting neurodevelopmental deficits. In particular, data have shown that prenatal alcohol exposure can reprogram neurobiological systems, altering developmental trajectories and resulting in increased vulnerability to adverse neurobiological, behavioral and health outcomes. Increasing evidence suggests that epigenetic mechanisms are potential mediators for the reprogramming of neurobiological systems, as they may provide a link between the genome, environmental conditions and neurodevelopmental outcomes. This review outlines the current state of epigenetic research in fetal alcohol spectrum disorder, highlighting the role of epigenetic mechanisms in the reprogramming of neurobiological systems by alcohol and as potential diagnostic tools for fetal alcohol spectrum disorder. We also present an assessment of the current limitations in studies of prenatal alcohol exposure, and highlight the future steps needed in the field.Entities:
Keywords: FASD; animal models; clinical cohorts; development; epigenetics; fetal programming; prenatal alcohol exposure
Mesh:
Year: 2017 PMID: 28234026 PMCID: PMC5549650 DOI: 10.2217/epi-2016-0163
Source DB: PubMed Journal: Epigenomics ISSN: 1750-192X Impact factor: 4.778
Overview of the mechanisms underlying fetal programming by prenatal alcohol exposure.
Ethanol exposure can have both direct effects on cellular programs through intracellular pathways, and indirect effects through the stimulation of various physiological systems, which release signaling molecules that can affect cellular functions. Cell death may play a role in the reprogramming of physiological systems, but is not depicted here. Together, these likely play a role in the biological embedding of PAE, with long-term consequences on health and behavior. Importantly, epigenetic mechanisms may mediate these effects through ethanol-dependent alterations in chromatin states. Chromatin, located in the cell’s nucleus, dynamically influences gene expression to modulate cellular functions. Transcriptionally active epigenetic states involve the presence of pro-transcriptional histone modifications and gene body DNA methylation. Micro-RNA (miRNA) provide an additional layer of regulation by modulating protein levels through translational inhibition. By contrast, transcriptionally inactive chromatin landscapes are associated with promoter DNA methylation, which can inhibit transcription factor binding and recruit methyl-binding proteins that promote anti-transcriptional histone modifications through their association with histone-modifying complexes. Nevertheless, the relationship between epigenetic states and transcription remains extremely complex, and this figure is merely a simplified representation of epigenetic regulation (expanded from our previous review [27]).
DNA modification studies of developmental alcohol exposure.
| Bulk | A | 3 g/kg (2×/day) | Gavage | GD 9–11 | Mouse | Whole fetus | N | GD 11 | ND | ↓ | DNA methylation | [ |
| ↓ | DNMT1 activity | |||||||||||
| A | 3 g/kg (1×/day) | Intragastric intubation | PN 2–10 | Rat | Hippocampus/prefrontal cortex | N | PN 21 | Male/female | ↑ | DNA methylation | [ | |
| A | 4.5 g/kg | Gavage | GD 1–22 | Rat | Hippocampus | N | PN 21 | Male/female | ↑ | DNMT activity | [ | |
| M | 4% v/v ethanol | Liquid diet | GD 1–17 | Mouse | Hippocampus | N | GD 17 | ND | ↑ | DNAm/DNAhm of CA1 cells, intermediate zone (DNAm only) | [ | |
| ↓ | DNAm/DNAhm of NE | |||||||||||
| PN 7 | ND | ↑ | DNAm of outer granule layer | |||||||||
| ↓ | DNAhm of outer and inner granule layer cells | |||||||||||
| A | ||||||||||||
| 200 mM | 2 days | NA | Mouse | Embryonic fibroblast (NIH/3T3) | Y | GD 13.5 | ND | ↓ | DNA methylation | [ | ||
| ↓ | ||||||||||||
| A | ||||||||||||
| 2.5 g/kg (2× at 0 h and 2 h) | Subcut. injection | PN 7 | Mouse | Hippocampus and neocortex | N | PN 7 | Male/female | ↓ | DNA methylation | [ | ||
| ↓ | ||||||||||||
| | A | 70 mM | 8 days | GD 14.5 | Mouse | Neural stem cells | Y | NA | NA | ↑ | DNA methylation | [ |
| Targeted | M | 5.0 g/kg | Liquid diet | GD 1–18 | Rat | Astrocyte | Y | GD 21 | Male/female | ↑ | [ | |
| A | 6.0 g/kg | Intragastric intubation | GD 1–20 | Rat | Olfactory bulb | N | PN 10 | Male/female | ↑ | [ | ||
| M | 10% v/v ethanol | Free drinking | GD 0.5–8.5 | Agouti mouse | Tail | N | PN 21 | Male/female | ↑ | Avy IAP DNA methylation | [ | |
| A | 5.8 g/kg | Intragastric intubation | GD 9 | Mouse | Embryo | N | GD 17 | Male | ↓ | [ | ||
| ↑ | ||||||||||||
| M | 6.7% v/v ethanol | Liquid diet | GD 7–21 | Rat | Mediobasal hypothalamus | N | PN 60–65 | Male | ↑ | [ | ||
| M | 10% v/v ethanol | Free drinking | GD 0.5–8.5 | Mouse | Hippocampus | N | PN 87 | Male | ↓ | [ | ||
| M | 10% v/v ethanol | Free drinking | GD 0.5–8.5 | Mouse | Hippocampus | N | PN 28 | Male | ↑ | DNAm | [ | |
| ↓ | DNAm | |||||||||||
| A | 70 mM | 8 days | GD 14.5 | Mouse | Neural stem cells | Y | NA | NA | DNAm | [ | ||
| | M | 35.5% ethanol-derived calories | Liquid diet | GD 1–22 | Rat | Hippocampus | N | PN 55 | Male/female | ↑ | DNAm | [ |
| Genome wide | A | 400 mg/dl | 44 h | GD 8.25 | Mouse | Embryo | Y | GD 10 | ND | ↑ | 1028 genes DNA methylation | [ |
| ↓ | 1136 genes DNA methylation | |||||||||||
| A | 400 mg/dl | 2 days | NA | Mouse | NS-5 neural stem cells | Y | NA | ND | ↑ | DNAm in 83 cell cycle genes | [ | |
| A | 400 mg/dl | 6 h | NA | Rat | DRG-derived neural stem cells | Y | NA | ND | ↓ | NSC gene DNAm | [ | |
| M | 20 mM | 4 days | NA | Human | Embryonic stem cells | Y | NA | ND | No changes in DNA methylation at 27,000 CpGs | [ | ||
| M | 10% v/v ethanol | Free drinking | GD 1- PN10 | Mouse | Whole brain | N | PN 70 | Male | 6660 differentially methylated promoters | [ | ||
| M or A | 20 mM or 50 mM | 1 or 2 days | NA | Human | Embryonic stem cells | Y | NA | Male/female | DNA hypermethylation at TSS and CpG islands, but inconsistent across individual regions | [ | ||
| A | 2.5 g/kg (2× at 0 and 2 h) | Subcut. injection | PN 4,7 | Mouse | Hippocampus | N | PN 70 | Male | 4640 differentially methylated regions in gene promoters and 459 in CpG islands | [ | ||
| Confirmed FASD | Human | Buccal epithelial cells | N | 3–6 years | Male | 269 differentially methylated CpGs | [ | |||||
| Confirmed PAE | Human | Buccal epithelial cells | N | 5–18 years | Male/female | 356 hypomethylated CpGs 302 hypermethylated CpGs | [ | |||||
A: Acute; DNAm: DNA methylation; DNAhm: DNA hydroxymethylation; GD: Gestational day; M: Moderate; NA: Not applicable; ND: Not disclosed; NE: Neuroepithelium; PN: Postnatal day.
Studies of chromatin alterations in response to developmental alcohol exposure.
| Bulk | M | 4 h/day | Inhalation chamber | PN | Rat | Cerebellum | N | PN 2, 4, 6, 8, 10, 12 | Male/female | ↓ | H3ace, H4ace, H3K23ace | [ |
| ↑ | ||||||||||||
| M or A | 50 or 200 mM ethanol | 24 h | NA | Mouse | Cardiac progenitor cells | Y | NA | ND | ↑ | H3K9ace | [ | |
| M | 6.7% v/v ethanol | Liquid diet | GD | Rat | POMC neurons of the arcuate nucleus | N | PN 60–80 | Male/female | ↑ | H3K9me2, G9a, | [ | |
| ↓ | H3K4me2/3, H3K9ace | |||||||||||
| A | 262.5 mM | 24 h | 48–72 hpf | Zebrafish | Embryo | N | 72 hpf | Male/female | ↑ | Phosphorylated histone H3 | [ | |
| M | 6.7% v/v ethanol | Liquid diet | GD | Rat | β-endorphin neurons of the arcuate nucleus | N | PN 60–65 | Male | ↑↓ | H3K9me2 H3K4me2/3, H3K9ace, H3S10phospho | [ | |
| A | 2.5 g/kg (2× at 0 and 2h) | Subcut. injection | PN 7 | Mouse | Hippocampus & Neocortex Neocortex | N | PN 7 | Male/female | ↑ | H3K9me2, H3K27me2 | [ | |
| ↑ | ||||||||||||
| M | 1.0 g/kg (2× at 0 and 2 h) | Subcut. injection | PN 7 | Mouse | Hippocampus & Neocortex | N | PN 7 | ND | ↑ | H3K9me2, H3K27me2 | [ | |
| A | 6 g/kg | Intragastric intubation | GD | Mouse | Fetal heart | N | GD 14.5 | Male/female | ↑ | H3K14ace | [ | |
| A | 5 g/kg | Intragastric intubation | GD 8.5–16.5 | Mouse | Fetal heart | N | GD 14.5 | Male/Female | ↑ | H3K9ace | [ | |
| | A | 5.0 g/kg (2× at 0 and 2h) | Subcut. injection | PN 7 | Mouse | Cerebral cortex | N | PN 7 | Male | ↑ | H2AX serine 139 phosphorylation | [ |
| Methyl-binding proteins | A | 200 mM | 2 days | NA | Mouse | Embryonic fibroblast (NIH/3T3) | Y | GD 13.5 | ND | ↓ | [ | |
| A | 6 g/kg (2× at 0 and 6h) | Intragastric intubation | GD 6–15 | Mouse | Cortex & Striatum | N | 5 weeks | Male/female | ↓ | MeCP2 levels | [ | |
| A | 70 mM | 8 days | GD 14.5 | Mouse | Neural stem cells | Y | NA | NA | ↑ | MeCP2 levels | [ | |
| | A | 300 mM | 6 days | 0–6 dpf | Brain | N | 6 dpf | Male/female | ↑ | [ | ||
| Targeted | A | 320 mg/dl | 5 days | GD 12.5 | Mouse | Fetal cerebral cortical neuroepithelial stem cells | Y | NA | ND | ↓ | H3K4me3, H3K27me3 of NSC/hemeobox genes and transposable elements | [ |
| M | 1.0 g/kg (2× at 0 and 2h) | Subcut. injection | PN 7 | Mouse | Hippocampus and neocortex | N | PN 7 | ND | ↑ | H3K14ace of | [ | |
| A | 5 g/kg | Intragastric intubation | GD 8.5–16.5 | Mouse | Fetal heart | N | GD 14.5 | Male/female | ↑ | H3K9ace of | [ | |
| A | 2.9 g/kg (2× at 0 and 4 h) | IP injection | GD 7 | Mouse | Cortex | N | GD 17 | ND | ↑ | H3K9ace of NSC/hemeobox genes | [ | |
| ↓ | H3K27me3 of NSC/hemeobox genes | |||||||||||
| A | 160 or 240 mg/dl | 3 days | GD 12.5 | Mouse | Fetal cerebral cortical neuroepithelial stem cells (GD 12.5) | Y | NA | ND | ↑↓ | Dose-dependent alterations to H3K4me3, H3K9ace, H3K9me2, H3K27me3 in NSC genes | [ | |
| A | 2.5 g/kg (2× at 0 and 2 h) | Subcut. injection | PN 7 | Mouse | Hippocampus and neocortex | N | PN 7 | ND | ↑↓ | H4K8ace of | [ | |
| | M | 10% v/v ethanol | Free drinking | GD 0.5–8.5 | Mouse | Hippocampus | N | PN 87 | Male | ↑ | [ | |
| Genome-wide | A | 2.5 g/kg (2× at 0 and 2 h) | Subcut. injection | PN 7 | Mouse | Hippocampus | N | PN 70 | Male | Widespread alterations to H3K4me3 (798 genes) and H3K27me3 (223 genes) – little overlap | [ | |
A: Acute; Dpf: Day post-fertilization; GD: Gestational day; G-W: Genome-wide; Hpf: Hours past fertilization; M: Moderate; NA: Not applicable; ND: Not disclosed; PN: Postnatal day.
Micro-RNA studies of developmental alcohol exposure.
| A | 320 mg/dl | 5 days | GD 12.5 | Mouse | Cerebral cortical NPC | Y | NA | ND | ↓ | 9, 21, 153, 335 | [ |
| L to A | 2.0, 4.0 or 6.0 g/kg (2× at 0 and 2 h) | Gavage | GD 6–15 | Mouse | Fetal brain | N | GD 17.5 | ND | ↑ | 9, 10a, 10b, 30a-3p, 145, 152 | [ |
| | | | | | | | | | ↓ | 29c, 30e-5p, 154, 200a, 296, 339, 362, 496 | |
| A | 1 or 1.5% ethanol | NA | 4–24 hpf | Zebrafish | Embryo | N | 24 hpf | ND | ↑ | 30d, 153a, 183, 736 | [ |
| | | | | | | | | | ↓ | 23a | |
| A | 320 mg/dl | 5 days | GD 12.5 | Mouse | Cerebral cortical NPC | Y | NA | ND | ↓ | 9, 21, 153, 335, 140–3p | [ |
| A | 2.5 g/kg (2× at 0 and 2 h) | Subcut. injection | PN 4, 7 | Mouse | Whole brain | N | PN 60 | Male | ↑ | 26b | [ |
| A | 430 mM | NA | 3.5–7.5 hpf | Zebrafish | Embryo | N | 24, 48, 72 hpf | Male/female | ↑ | pre-9–3 (precursor to 9) | [ |
| | | | | | | | | | ↓ | 9 | |
| M | 10% v/v ethanol | Free drinking | GD 1 - PN 10 | Mouse | Whole brain | N | PN 70 | Male | ↑ | 679–5p | [ |
| A | 400 mg/dl | 24 or 48 h | PN 7 | Mouse | Cerebellar granule neurons | Y | PN 7 | ND | ↑ | 34a, 181a | [ |
| | | | | | | | | | ↓ | 9, 29a, 29b, 133 | |
| A | 2.5 g/kg (2× at 0 and 2 h) | Subcut injection | GD 14, 16 | Mouse | Whole brain | N | PN 70 | Male | ↑ | 302c | [ |
| A | 2.9 g/kg at 0 h 1.45 g/kg at 2 h | IP injection | GD 12 | Rat | Amygdala and ventral striatum | N | PN 42 | Male/female | ↑ | 34c, 155, 542–1, let-7c-1, let7c-2–3p | [ |
| | | | | | | | | | ↓ | 9a-2, 29c-3p, 191–1, 138–2, 221–5p, 322–2, 384–5p, 412–3p, 496, 874–5p 1843a-3p | |
| A | 1.75 g/kg (1 h/day × 3 days/week) | Intravenous catheter | GD | Sheep | Plasma | N | GD 147 | Male/female | ↑ | 34b | [ |
| | | | | | | | | | ↓ | 9, 15b, 17–92, 572, 720 | |
| M | 10% v/v ethanol | Free drinking | GD | Mouse | Hippocampus | N | PN 87 | Male | ↑ | 135a, 135b, 467b-5p, 487b | [ |
| Heavily prenatally exposed and affected children | Human | Maternal plasma | N | NA | Female | ↑ | 187–5p, 204–5p, 222–5p, 299–3p, 449, 491–3p, 518f-3p, 519a-3p, 671–5-. 760, 885–3p | [ | |||
A: Acute; GD: Gestational day; L: Low; Hpf: hours past fertilization; M: Moderate; NA: Not applicable; ND: Not disclosed; NPC: Neural progenitor cell; PN: Postnatal day.